Melanoma - KOL Insight

Table of Contents

Executive summary (7)

Treatment algorithm (1)

Research objectives (2)

Marketed therapies (35)

• Overview
• Immunotherapies (35)
  • Opdivo/Yervoy (nivolumab/ipilimumab; Bristol Myers Squibb/Ono Pharmaceuticals) (14)
  • Opdualag (nivolumab/relatlimab; Bristol Myers Squibb) (13)
  • Keytruda (pembrolizumab; Merck & Co.) (8)

BRAF/MEK inhibitors (9)

• Overview (3)
  • Key insights summary (2)
• Marketed BRAF/MEK drugs (6)
  • Tafinlar/Mekinist (dabrafenib/trametinib; Novartis) (1)
  • Cotellic/Zelboraf (cobimetinib/vemurafenib; Roche) (1)
  • Braftovi/Mektovi (encorafenib/binimetinib; Array BioPharma) (4)

Oncolytic viruses/immunostimulants (7)

• Overview (7)
  • Imlygic (T-VEC/talimogene laherparepvec; Amgen) (6)

Pipeline therapies

• Overview

Immune checkpoint inhibitors (12)

• Overview (12)
  • Key insights summary (2)
  • Libtayo ([cemiplimab)]/fianlimab; Regeneron) (1)
  • Keytruda ([pembrolizumab]/vibostolimab; Merck & Co.) (9)

Recombinant immunostimulants (19)

• Overview (19)
  • Key insights summary (3)
  • mRNA-4157 (personalized cancer vaccine; Moderna) (1)
  • Nidlegy (bifikafusp alfa + onfekafusp alfa; Philogen) (14)

Toll-like receptor 9 (TLR9) agonists (8)

• Overview (8)
  • Key insights summary (7)

Immunologic cytotoxicity/T lymphocyte stimulants (10)

• Overview (10)
  • Key insights summary (2)
  • Kimmtrak (tebentafusp; Immunocore/Medison Pharma) (7)

Histone deacetylase (HDAC) inhibitor (7)

• Overview (7)
  • Key insights summary (2)
  • Epidaza/Hiyasta (tucidinostat; HUYA Bioscience International) (5)

Tumour infiltrating lymphocyte (TIL) cell therapy (11)

• Key insights summary (11)
  • Iovance's Contego TIL therapy excites KOLs as another potential option in the PD1-refractory setting (8)

Appendix (4)

• KOL details (4)
  • KOLs from the USA (1)
  • KOLs from Australia/Europe (2)